IDiyas

For the Inventor, By the Inventor

Breda, Netherlands

Peter Jacobus Johannes Antonius Buijnsters

USPTO Granted Patents = 13 

Average Co-Inventor Count = 7.3

ph-index = 5

Forward Citations = 151(Granted Patents)


Location History:

  • 2340 Beese, BE (2007)
  • Etten-Leur, NL (2012)
  • Etten-Leur, BE (2010 - 2013)
  • JX Breda, NL (2014)
  • Breda, NL (2007 - 2016)
  • Beerse, BE (2020)

Company Filing History:

goldMedal12 out of 2,076 
 
Janssen Pharmaceutica Nv
 patents
silverMedal1 out of 832,680 
Other
 patents

Years Active: 2007-2020

Loading Chart...
13 patents (USPTO):Explore Patents
1. 10604523 - 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives (2020-03-31),
2. 9273013 - Quinazoline derivatives (2016-03-01),
3. 8778920 - 3-cyano-quinoline derivatives with antiproliferative activity (2014-07-15),
4. 8394786 - Quinazoline derivatives (2013-03-12),
5. 8338422 - Indolin-2-ones and aza-indolin-2-ones (2012-12-25),
6. 8318929 - 4-aryl-2-anilino-pyrimidines (2012-11-27),
7. 7803823 - 2-amino-4,5-trisubstituted thiazolyl derivatives (2010-09-28),
8. 7648975 - Macrocyclic quinazoline derivatives as antiproliferative agents (2010-01-19),
9. 7560458 - Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors (2009-07-14),
10. 7514445 - Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) (2009-04-07),
11. 7449465 - Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors (2008-11-11),
12. 7232838 - 2-amino-4,5-trisubstituted thiazolyl derivatives (2007-06-19),
13. 7183288 - Amide derivatives as glycogen synthase kinase 3-β inhibitors (2007-02-27),

Title: Peter Jacobus Johannes Antonius Buijnsters: Innovator in Pharmaceutical Chemistry

Introduction

Peter Jacobus Johannes Antonius Buijnsters is a notable inventor based in Breda, Netherlands. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 13 patents. His work primarily focuses on developing novel compounds that have potential therapeutic applications.

Latest Patents

Among his latest innovations, Buijnsters has developed 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives. This invention relates to novel compounds that act as inhibitors of phosphodiesterase 2 (PDE2) and phosphodiesterase 10 (PDE10). These compounds are aimed at treating disorders associated with these enzymes, including neurological and psychiatric disorders, as well as endocrinological or metabolic diseases. Additionally, his work includes the development of radiolabelled compounds for imaging and quantifying the PDE2 enzyme in tissues using positron-emission tomography (PET). Another area of his research involves quinazoline derivatives, which are also aimed at therapeutic applications.

Career Highlights

Throughout his career, Buijnsters has worked with prominent companies, including Janssen Pharmaceutica NV. His experience in the pharmaceutical industry has allowed him to contribute to various innovative projects and advancements in drug development.

Collaborations

Buijnsters has collaborated with notable colleagues such as Eddy Jean Edgard Freyne and Werner Constant Johan Embrechts. These partnerships have further enriched his research and development efforts in the pharmaceutical field.

Conclusion

Peter Jacobus Johannes Antonius Buijnsters is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in the treatment of various disorders. His innovative patents and collaborations highlight his commitment to improving healthcare through scientific research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…